azacitidine zentiva 25 mg/ml injektiokuiva-aine, suspensiota varten
zentiva k.s. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini
azacitidine stada 25 mg/ml injektiokuiva-aine, suspensiota varten
stada arzneimittel ag - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini
onureg
bristol-myers squibb pharma eeig - atsakitidiini - leukemia, myeloidi, akuutti - antineoplastiset aineet - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
azacitidine sun 25 mg/ml injektiokuiva-aine, suspensiota varten
sun pharmaceutical industries europe b.v. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini
azacitidine lorien 25 mg/ml injektiokuiva-aine, suspensiota varten
laboratorios lorien s.l. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini
azacitidine ever pharma 25 mg/ml injektiokuiva-aine, suspensiota varten
ever valinject gmbh - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini
etraga 25 mg/ml injektiokuiva-aine, suspensiota varten
stada arzneimittel ag - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini
vidaza
bristol-myers squibb pharma eeig - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
azacitidine celgene
celgene europe bv - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.
azacitidine betapharm
betapharm arzneimittel gmbh - atsakitidiini - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiset aineet - atsasitidiini betapharm on tarkoitettu aikuispotilaille, jotka eivät ole oikeutettuja hematopoieettiset kantasolusiirto (hsct) kanssa:intermediate-2 ja korkean riskin myelodysplastinen oireyhtymä (mds) mukaan international prognostic scoring system (ipss),krooninen myelomonocytic leukemia (cmml) 10 % 29 % luuytimen räjäytykset ilman myeloproliferative häiriö,akuutti myelooinen leukemia (aml), jossa on 20 % 30 % blasteja ja multi-lineage dysplasia, mukaan maailman terveysjärjestön (who) luokitukseen,aml > 30 % luuytimessä blasteja who: n luokitus.